Table 4 Thirty- day crude occurrence of net adverse clinic events
Short-time group(n = 432) | Long-time group(n = 992) | Hazard Ratio (95% CI) | P value | |
|---|---|---|---|---|
MACCEs (n,%) | 13 (3.0%) | 38 (3.8%) | 0.42–1.48 | 0.54 |
Death (n,%) | 3 (0.69%) | 7 (0.71%) | 0.26–3.83 | 1.00 |
Myocardial infarction (n,%) | 8 (1.9%) | 29 (2.9%) | 0.28–1.38 | 0.28 |
STEMI | 2 (0.5%) | 10 (1.0%) | 0.09–2.09 | 0.53 |
NSTEMI | 6 (1.4%) | 19 (1.9%) | 0.29–1.81 | 0.66 |
Definite/ Probable Stent thrombosis (n,%) | 3 (0.7%) | 9 (0.9%) | 0.21–2.84 | 1.00 |
Stroke (n,%) | 5 (1.2%) | 14 (1.4%) | 0.29–2.82 | 0.80 |
Bleeding and access related complications (n,%) | 24 (5.6%) | 77 (7.8%) | 0.44–1.12 | 0.15 |
Major Bleeding | 7 (1.6%) | 20 (2.0%) | 0.34–1.91 | 0.68 |
Arteriovenous fistula | 2 (0.46%) | 15 (1.50%) | 0.07–1.33 | 0.11 |
False aneurysm | 5 (1.2%) | 18 (1.8%) | 0.23–1.72 | 0.49 |
Hematoma | 11 (2.5%) | 29 (2.9%) | 0.43–1.75 | 0.86 |
Net adverse clinic events (n,%) | 37 (8.6%) | 115 (11.6%) | 0.49–1.05 | 0.09 |